RELB

Across TCGA pan-cancer cohorts, RELB mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RELB data layer compared with 29 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher RELB mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RELB expression acts as an unfavorable survival marker.

GBM, PDAC, and HNSC are the cancer types where RELB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Quartile	All	0.386	0.713	.001	7	view →
PDAC	DFS	Median	III,IV	0.353	0.666	.034	6	view →
HNSC	DFS	Median	III,IV	0.720	0.879	.033	3	view →
LUAD	OS	Tertile	III,IV	0.236	0.665	.037	2	view →
CCRCC	OS	Tertile	All	0.678	1.000	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RELB–GBM (OS)

Open the GBM breakdown →